Page last updated: 2024-11-02

pioglitazone and Lipid Metabolism Disorders

pioglitazone has been researched along with Lipid Metabolism Disorders in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Lipid Metabolism Disorders: Pathological conditions resulting from abnormal anabolism or catabolism of lipids in the body.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wang, JM1
Wang, D1
Tan, YY1
Zhao, G1
Ji, ZL1

Other Studies

1 other study available for pioglitazone and Lipid Metabolism Disorders

ArticleYear
Pioglitazone reduces lipid droplets in cholesterolosis of the gallbladder by increasing ABCA1 and NCEH1 expression.
    Molecular and cellular biochemistry, 2015, Volume: 399, Issue:1-2

    Topics: ATP Binding Cassette Transporter 1; Carboxylic Ester Hydrolases; Cell Survival; Cells, Cultured; Dru

2015